Expression of IGFBP-3 by human retinal endothelial cell cultures: IGFBP-3 involvement in growth inhibition and apoptosis

Investigative Ophthalmology and Visual Science

Volumn 44, Issue 1, 2003, Pages 365-369

  Spoerri, Polyxenie E ^a   Caballero, Sergio ^a   Wilson, Sylvia H ^a   Shaw, Lynn C ^a   Grant, Maria B ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROCHROME; GROWTH HORMONE; HORMONE RECEPTOR STIMULATING AGENT; IMMUNOGLOBULIN G; L 779976; L 779978; LIPOCORTIN 5; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CULTURE MEDIUM; DIABETIC RETINOPATHY; DISEASE COURSE; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LOW LEVEL LASER THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RETINA;

AMIDES; ANNEXIN A5; APOPTOSIS; CELL CULTURE TECHNIQUES; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; INDOLES; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; NITROBENZENES; RECEPTORS, SOMATOSTATIN; RECOMBINANT PROTEINS; RETINAL VESSELS; TETRAZOLIUM SALTS; THIAZOLES;

EID: 0037250470     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.02-0309     Document Type: Article

References (54)

1. Merimee TJ. A follow-up study of vascular disease in growthhormone-deficient dwarfs with diabetes. N Engl J Med. 1978;298:1217-1222.
2. Dills DG, Moss SE, Klein R, Klein BE. Association of elevated IGF-I levels with increased retinopathy in late-onset diabetes. Diabetes. 1991;40:1725-1730.
3. Grant MB, Russell B, Fitzgerald C, Merimee TJ. Insulin-like growth factors in vitreous: studies in control and diabetic subjects with neovascularization. Diabetes. 1986;35:416-420.
4. Smith LE, Kopchick JJ, Chen W, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science. 1997;276:1706-1709.
5. Grant MB, Mames RN, Fitzgerald C, et al. Insulin-like growth factor I as an angiogenic agent: in vivo and in vitro studies. Ann NY Acad Sci. 1993;692:230-242.
6. Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973;179:77-79.
7. Hyer SL, Sharp PS, Brooks RA, Burrin JM, Kohner EM. Continuous subcutaneous octreotide infusion markedly suppresses IGF-I levels whilst only partially suppressing GH secretion and diabetics with retinopathy. Acta Endocrinol (Copenh). 1989;120:187-194.
8. Baxter RC. Insulin-like growth factor binding proteins in the human circulation: a review. Horm Res. 1994;42:140-144.
9. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995:3-34.
10. Ferry RJ Jr, Katz LE, Grimberg A, Cohen P, Weinzimer SA. Cellular actions of insulin-like growth factor binding proteins. Horm Metab Res. 1999;31:192-202.
11. Ballard FJ, Knowles SE, Walton PE, et al. Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I), IGF-II and des (1-3)IGF-I in rats. J Endocrinol. 1991;128:197-204.
12. Grimberg A. P53 and IGFBP-3: apoptosis and cancer protection. Mol Genet Metab. 2000;70:85-98.
13. Valentinis B, Bhala A, DeAngelis T, Baserga R, Cohen P. The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol Endocrinol. 1995;9:361-367.
14. Wraight CJ, Murashita MM, Russo VC, Werther GA. A keratinocyte cell line synthesizes a predominant insulin-like growth factor-binding protein (IGFBP-3) that modulates insulin-like growth factor-I action. J Invest Dermatol. 1994;103:627-631.
15. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem. 1997;272:12181-12188.
16. Lalou C, Lassarre C, Binoux M. A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology. 1996;137:3206-3212.
17. Dong G, Rajah R, Vu T, et al. Decreased expression of Wilms' tumor gene WT-1 and elevated expression of insulin growth factor-II (IGF-II) and type 1 IGF receptor genes in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab. 1997;82:2198-2203.
18. Katz J, Nasatzky E, Werner H, Le Roith D, Shemer J. Tumor necrosis factor alpha and interferon gamma-induced cell growth arrest is mediated via insulin-like growth factor binding protein-3. Growth Horm IGF Res. 1999;9:174-178.
19. Cohen P, Nunn SE, Peehl DM. Transforming growth factor-beta induces growth inhibition and IGF-binding protein-3 production in prostatic stromal cells: abnormalities in cells cultured from benign prostatic hyperplasia tissues. J Endocrinol. 2000;164:215-223.
20. Gucev ZS, Oh Y, Kelley KM, Rosenfeld RG. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. Cancer Res. 1996;56:1545-1550.
21. Han GR, Dohi DF, Lee HY, et al. All-trans-retinoic acid increases transforming growth factor-beta2 and insulin-like growth factor binding protein-3 expression through a retinoic acid receptor-alpha-dependent signaling pathway. J Biol Chem. 1997;272:13711-13716.
22. Lawnicka H, Stepien H, Wyczolkowska J, Kolago B, Kunert-Radek J, Komorowski J. Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture. Biochem Biophys Res Commun. 2000;268:567-571.
23. Danesi R, Del Tacca M. The effects of the somatostatin analog octreotide on angiogenesis in vitro. Metabolism. 1996;45:49-50.
24. Danesi R, Agen C, Benelli U, et al. Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). Clin Cancer Res. 1997;3:265-272.
25. Mallet B, Vialettes B, Haroche S, et al. Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995. Diabetes Metab. 1992;18:438-444.
26. Grant MB, Mames RN, Fitzgerald C, et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care. 2000;23:504-509.
27. Davis MI, Wilson SH, Grant MB. The therapeutic problem of proliferative diabetic retinopathy: targeting somatostatin receptors. Horm Metab Res. 2001;33:295-299.
28. Medina DL, Toro MJ, Santisteban P. Somatostatin interferes with thyrotropin-induced G1-S transition mediated by cAMP-dependent protein kinase and phosphatidylinositol 3-kinase: involvement of RhoA and cyclin E x cyclin-dependent kinase 2 complexes. J Biol Chem. 2000;275:15549-15556.
29. Pages P, Benali N, Saint-Laurent N, et al. Sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip 1): evidence for the role of SHP-1. J Biol Chem. 1999;274:15186-15193.
30. Reardon DB, Dent P, Wood SL, Kong T, Sturgill TW. Activation in vitro of somatostatin receptor subtypes 2, 3, or 4 stimulates protein tyrosine phosphatase activity in membranes from transfected Ras-transformed NIH 3T3 cells: coexpression with catalytically inactive SHP-2 blocks responsiveness. Mol Endocrinol. 1997;11:1062-1069.
31. Wilson SH, Davis MI, Caballero S, Grant MB. Modulation of retinal endothelial cell behaviour by insulin-like growth factor I and somatostatin analogues: implications for diabetic retinopathy. Growth Horm IGF Res. 2001;11(suppl A):S53-S59.
32. Grant MB, Guay C. Plasminogen activator production by human retinal endothelial cells of nondiabetic and diabetic origin. Invest Ophthalmol Vis Sci. 1991;32:53-64.
33. Grant MB, Caballero S, Bush DM, Spoerri PE. Fibronectin fragments modulate human retinal capillary cell proliferation and migration. Diabetes. 1998;47:1335-1340.
34. Spoerri PE, Ellis EA, Tarnuzzer RW, Grant MB. Insulin-like growth factor: receptor and binding proteins in human retinal endothelial cell cultures of diabetic and nondiabetic origin. Growth Horm IGF Res. 1998;8:125-132.
35. Jaques G, Noll K, Wegmann B, et al. Nuclear localization of insulin-like growth factor binding protein 3 in a lung cancer cell line. Endocrinology. 1997;138:1767-1770.
36. Schedlich LJ, Young TF, Firth SM, Baxter RC. Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. J Biol Chem. 1998;273:18347-18352.
37. Wraight CJ, Liepe IJ, White PJ, Hibbs AR, Werther GA. Intranuclear localization of insulin-like growth factor binding protein-3 (IGFBP-3) during cell division in human keratinocytes. J Invest Dermatol. 1998;111:239-242.
38. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994;84:1415-1420.
39. Bratton DL, Fadok VA, Richter DA, Kailey JM, Guthrie LA, Henson PM. Appearance of phosphatidylserine on apoptotic cells requires calcium-mediated nonspecific flip-flop and is enhanced by loss of the aminophospholipid translocase. J Biol Chem. 1997;272:26159-26165.
40. Gatti R, Belletti S, Orlandini G, Bussolati O, Dall'Asta V, Gazzola GC. Comparison of annexin V and calcein-AM as early vital markers of apoptosis in adherent cells by confocal laser microscopy. J Histochem Cytochem. 1998;46:895-900.
41. Gill ZP, Perks CM, Newcomb PV, Holly JM. Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. J Biol Chem. 1997;272:25602-25607.
42. Oh Y, Muller HL, Lamson G, Rosenfeld RG. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem. 1993;268:14964-14971.
43. Yamanaka Y, Fowlkes JL, Wilson EM, Rosenfeld RG, Oh Y. Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule. Endocrinology. 1999;140:1319-1328.
44. Leal SM, Liu Q, Huang SS, Huang JS. The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor. J Biol Chem. 1997;272:20572-20576.
45. Fowke PJ, Hodgkinson SC. The ovine pancreatic protein which binds insulin-like growth factor binding protein-3 is procarboxypeptidase A. J Endocrinol. 1996;150:51-56.
46. Weinzimer SA, Gibson TB, Collett-Solberg PF, Khare A, Liu B, Cohen P. Transferrin is an insulin-like growth factor-binding protein-3 binding protein. J Clin Endocrinol Metab. 2001;86:1806-1813.
47. Campbell PG, Durham SK, Hayes JD, Suwanichkul A, Powell DR. Insulin-like growth factor-binding protein-3 binds fibrinogen and fibrin. J Biol Chem. 1999;274:30215-30121.
48. Yang YW, Yanagishita M, Rechler MM. Heparin inhibition of insulin-like growth factor-binding protein-3 binding to human fibroblasts and rat glioma cells: role of heparan sulfate proteoglycans. Endocrinology. 1996;137:4363-4371.
49. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999;20:157-198.
50. Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci USA. 1992;89:251-255.
51. Yasuda K, Rens-Domiano S, Breder CD, et al. Cloning of a novel somatostatin receptor, SSTR3, coupled to adenylylcyclase. J Biol Chem. 1992;267:20422-20428.
52. Grant MB, Caballero S, Millard WJ. Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization. Regul Pept. 1993;48:267-278.
53. Sharma K, Patel YC, Srikant CB. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol. 1996;10:1688-1696.
54. Hollowood AD, Lai T, Perks CM, Newcomb PV, Alderson D, Holly JM. IGFBP-3 prolongs the p53 response and enhances apoptosis following UV irradiation. Int J Cancer. 2000;88:336-341.